ESR1 and breast carcinoma: In this context, particularly interesting was a study by Hsu et al. that reported the use of two PDX models that were isolated from two patients with HER2+/ER+ breast cancer and used to define a peculiar sensitivity of this tumor subtype to simultaneous suppression of both ER signaling and mTOR pathway, a potential combination treatment for these tumors [458].